Knight Therapeutics to Buy Regional Rights to Exelon
By Michael Dabaie
Knight Therapeutics Inc. said it would acquire the exclusive
rights to manufacture, market and sell Exelon in Canada and Latin
America from Novartis AG.
Montreal-based Knight said it is also acquiring an exclusive
license to use the intellectual property and the Exelon trademark
within the territory.
Exelon is a prescription product first approved in 1997 and is
currently registered and sold in about 90 countries. Exelon is
indicated for mild to moderately severe dementia in people with
Knight will pay $168 million in cash and an additional milestone
payment of up to $12 million.
Exelon had annual revenue for 2020 of about $47 million for
Canada and Latin America, Knight said.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
April 23, 2021 08:26 ET (12:26 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.